Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT00901901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Study identification
- NCT ID
- NCT00901901
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 732 participants
Conditions and interventions
Conditions
Interventions
- Erlotinib (Tarceva) Drug
- Placebo Drug
- Sorafenib (Nexavar, BAY43-9006) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2009
- Primary completion
- Apr 16, 2012
- Completion
- May 22, 2018
- Last update posted
- May 29, 2019
2009 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Atlanta | Georgia | 30318 | — |
| Not listed | Honolulu | Hawaii | 96817 | — |
| Not listed | Maywood | Illinois | 60153-5585 | — |
| Not listed | Westwood | Kansas | 66205 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | New Orleans | Louisiana | 70112 | — |
| Not listed | Baltimore | Maryland | 21202 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Boston | Massachusetts | 02215-5450 | — |
| Not listed | Worcester | Massachusetts | 01655 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Minneapolis | Minnesota | 55455 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Valhalla | New York | 10595 | — |
| Not listed | Charlotte | North Carolina | 28203 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00901901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2019 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00901901 live on ClinicalTrials.gov.